Jaeb Center for Health Research
Trial Pipeline
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
NCT06837181
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
NCT06790784
Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery
NCT06880835
CGM for the Early Detection and Management of Hyperglycemia in Pregnancy
NCT06957028
Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes
NCT06535789
T1D Pregnancy & Me
NCT06959316
Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
NCT06524882
Bionic Pancreas in CFRD
NCT06449677
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
NCT06380517
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
NCT05844982
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
NCT05904028
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
NCT05589714
Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM
NCT05145491
Fenofibrate for Prevention of DR Worsening
NCT04661358
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
NCT04378790
Gyrate Atrophy Ocular and Systemic Study
NCT05312736
Evaluation of Tonabersat for DME
NCT05727891
Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF
NCT05639556
Bevacizumab Treatment For Type 1 ROP
NCT04634578
Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F
NCT04765345
Rate of Progression in EYS Related Retinal Degeneration
NCT04127006
Rate of Progression in USH2A-related Retinal Degeneration
NCT03146078
Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes
NCT04233034
The Loop Observational Study
NCT03838900
Effects of Pneumatic Vitreolysis on Macular Hole
NCT03677869
Day and Night Closed-loop in Young People With Type 1 Diabetes
NCT02925299
Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
NCT02858076
Anti-VEGF Treatment for Prevention of PDR/DME
NCT02634333
A Prospective Observational Study of Adult Strabismus
NCT02510040
A Pilot Clinical Trial of Overminus Spectacle Therapy for Intermittent Exotropia
NCT02223650
Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use
NCT02137512
Hyperopia Treatment Study 1 (HTS1) - Glasses vs Observation
NCT01515475
An Outpatient Pump Shutoff Pilot Feasibility and Safety Study
NCT01736930
NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)
NCT01331005
Inpatient Evaluation of an Automated Closed-Loop Control-to-Range System
NCT01271023
Levodopa for the Treatment of Residual Amblyopia
NCT01190813
Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old
NCT00944710
Immediate Office Probing vs Deferred Facility Probing for Nasolacrimal Duct Obstruction in Children 6 to <10 Months Old
NCT00780741
Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes
NCT00406133
A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
NCT00336323
Study to Determine the Relationship Between Exercise and Hypoglycemia in Children With Type 1 Diabetes
NCT00109434
Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children
NCT00091923
Trial Comparing Part-time Versus Full-time Patching for Severe Amblyopia
NCT00094744
Trial Comparing Part-time Versus Minimal-time Patching for Moderate Amblyopia
NCT00094679
Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia
NCT00000170
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 34 |
| Phase 3 | 49 |
What the Pipeline for Jaeb Center for Health Research Shows
According to the ClinicalTrials.gov registry, Jaeb Center for Health Research is linked to 134 US clinical trials across every stage of research activity. Of those, 104 studies are currently recruiting — about 78% of the sponsor's indexed portfolio — and 23 are already marked complete, representing roughly 17% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Jaeb Center for Health Research reports 49 late-stage studies (Phase 3 and Phase 4 combined) and 35 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Jaeb Center for Health Research is Amblyopia with 9 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.